Medtronic Unveils New Brand Identity at the 4th China International Import Expo, Embarking on a New Journey in Healthcare Innovation

SHANGHAI, Oct. 15, 2021 /PRNewswire/ -- As the countdown to the 4th China International Import Expo (CIIE) begins, Medtronic, serving as a vice-chair member of the CIIE Medical Devices Professional Committee, will debut under the new brand theme "Life is Extraordinary Through Technology." The company will showcase over 60 of the world's leading medical technology innovations across seven key fields, highlighting global trends toward intelligent, digital, and minimally invasive medical technologies. By painting a vision of future healthcare, the exhibition underscores Medtronic's commitment to "continuously delivering extraordinary life experiences to patients through advanced medical technologies."”confidence.

Thanks to the platform of the China International Import Expo (CIIE), Medtronic's cutting-edge products and technologies have garnered widespread attention, accelerating the commercialization of these innovations in China and fully demonstrating the CIIE's spillover effect of "transforming exhibits into market-ready products": the Micra leadless pacemaker, which emerged as a "star exhibit" at the inaugural CIIE, has already achieved over 2,500 successful implantations in China. Medtronic's MAZOR X intelligent navigation robot for spinal surgery, showcased at the third CIIE, received regulatory approval in April 2021 and officially launched in the Chinese market in August, further advancing the implementation of Medtronic's "integrated intelligent orthopedic surgery" concept. The Symplicity Spyral catheter system, also exhibited at the previous expo,^*, under the "Nine Measures" pilot policy and introduced via a green channel, it has completed its first clinical application at Boao Super Hospital, marking an advancement in hypertension treatment from "pharmacotherapy alone" to "minimally invasive interventional therapy".

This year, Medtronic will not only showcase a brand-new corporate identity at this year's CIIE, but will also present a series of globally leading innovative solutions spanning seven key therapeutic areas: Cardiovascular, Surgical Innovations, Smart Healthcare, Neuroscience & Spine Surgery, Gastrointestinal & Hepatic, Renal Health, and Critical Care. Among them is the DIAMOND TEMP Ablation System (diamond-tip atrial fibrillation ablation system), making its Asia-Pacific debut.^*；Currently the drug-eluting coronary stent with the widest diameter range available worldwide: Resolute Onyx^*; and the world's first Percept PC Deep Brain Stimulation Neurostimulator capable of automatically detecting neurological disease states^*and other cutting-edge medical technology products. During the CIIE, Medtronic will also deepen collaboration with industry partners through a variety of on-site activities, sharing innovation opportunities.

In the new normal of the post-pandemic era, the China International Import Expo (CIIE) continues to serve as a vital window for the country to foster a domestic and international dual circulation paradigm, as well as a key platform for all sectors to strengthen economic and trade exchanges and cooperation, and promote mutual benefit and win-win outcomes. "The Chinese market has already become a global focal point, and we remain fully confident in the long-term market prospects of China's healthcare industry. Furthermore, the Chinese government's support in healthcare infrastructure development, the healthcare security system, and innovative R&D has revealed immense market potential to us. As one of the most representative measures among the Chinese government's numerous opening-up initiatives, the CIIE provides enterprises with a crucial stage to showcase their innovation," said Mr. Gu Yushao, Senior Vice President of Medtronic and President of Greater China:““We look forward to participating in the 4th China International Import Expo (CIIE) to seize new opportunities in the Chinese market under the new development paradigm, bring more cutting-edge therapies and technologies to China, and accelerate their implementation to serve Chinese patients.”

*This product has not been marketed in mainland China.